Clinical trial
TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low…
NCT00071097 · Tibotec Pharmaceuticals, Ireland, Industry · Completed
Key facts
| NCT number | NCT00071097 |
|---|---|
| Title | TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients |
| Official title | A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose Response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV. |
| Lead sponsor | Tibotec Pharmaceuticals, Ireland, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | TMC114/rtv |
| Enrollment | 330 |
| Start date | Oct 1, 2003 |
| Primary completion | Feb 1, 2005 |
| Completion | Nov 1, 2007 |
| First posted | Oct 15, 2003 |
| Last update posted | Sep 20, 2016 |
| Countries | Argentina, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: